4 Days
Source:
معلومات مباشر
Silkuti stock drops 19% after postponement of new cancer treatment launch
Shares of Silkwayt decreased by 19% after the postponement of the launch of their new breast cancer treatment, despite the U.S. Food and Drug Administration's approval of the drug "Gidetoliseeb," marketed as "Riftrebic," for a specific type of advanced breast cancer. The product was initially expected to be launched in the third quarter, but the company delayed the release to ensure sufficient quantities are available, without revealing the price, which is anticipated to be higher than current treatments. The drug has demonstrated significant clinical results, reducing the risk of disease progression or death by 76%, although some patients experience side effects such as severe mouth inflammation. Sales of the drug are expected to reach $36 million in 2026, with a monthly cost of approximately $28,000.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)